Stryker receives FDA clearance for OptaBlate™ Bone Tumor Ablation System
Retrieved on:
Tuesday, September 20, 2022
The New Orleans Medical and Surgical Journal, Interventional oncology, Twitter, NYSE, Food, SYK, LinkedIn, Population, Spine, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Attention, Physician, Technology, IVS, Stryker, Radiofrequency ablation, Interventional radiology, General manager, Diagnosis, BTA, Vimeo, Medical imaging
PORTAGE, Mich., USA, Sept. 20, 2022 /PRNewswire/ -- Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration. The addition of the OptaBlate technology to Stryker's Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.
Key Points:
- PORTAGE, Mich., USA, Sept. 20, 2022 /PRNewswire/ -- Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration.
- "Stryker's new bone tumor ablation (BTA) system is a significant improvement on existing technology and builds on Stryker's IVS portfolio," said Dr. Anthony Brown, a Vascular and Interventional Radiologist at Radiology Imaging Associates, CO. "There is no more deserving patient population for our attention and intervention; OptaBlate will change lives."
- As Stryker's first Interventional Oncology technology, OptaBlate optimizes all aspects of the procedurefrom set-up to ablation.
- The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs," said Greg Siller, Vice President and General Manager, Interventional Spine business, Stryker.